9 Meters Biopharma Q3 FY22: net loss $9.4M; diluted EPS −$14.40

Key figures from this report

These are the numbers 9 Meters Biopharma reported for Q3 FY22, the quarter ended Sep 30, 2022, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

1. Net income−$9.4MAgainst −$13.5M in Q3 FY2110-Q income statement, on EDGAR
2. Diluted EPS−$14.40Against −$1.00 in Q3 FY21. Split-adjusted, as the tables show it; the filing reported −$0.7210-Q income statement, on EDGAR
3. Cash and cash equivalents$15.9M−70% from $53.6M in Q3 FY2110-Q balance sheet, on EDGAR
4. Cash from operations−$10.0MAgainst −$8.2M in Q3 FY2110-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters